Hikari Power Ltd Raises Position in Akari Therapeutics PLC (AKTX)
Hikari Power Ltd increased its stake in Akari Therapeutics PLC (NASDAQ:AKTX) by 152.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 151,334 shares of the biopharmaceutical company’s stock after purchasing an additional 91,322 shares during the quarter. Hikari Power Ltd owned 1.28% of Akari Therapeutics PLC worth $929,000 at the end of the most recent quarter.
Separately, VHCP Management II LLC boosted its holdings in Akari Therapeutics PLC by 15.4% in the second quarter. VHCP Management II LLC now owns 426,297 shares of the biopharmaceutical company’s stock worth $1,965,000 after purchasing an additional 56,807 shares during the last quarter. 26.97% of the stock is currently owned by institutional investors.
Several equities research analysts recently issued reports on the stock. Zacks Investment Research cut shares of Akari Therapeutics PLC from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 26th. Chardan Capital restated a “neutral” rating on shares of Akari Therapeutics PLC in a report on Sunday, September 17th. William Blair upgraded shares of Akari Therapeutics PLC from a “market perform” rating to an “outperform” rating in a report on Friday, September 22nd. Canaccord Genuity restated a “buy” rating and issued a $15.00 target price on shares of Akari Therapeutics PLC in a report on Friday, September 22nd. Finally, ValuEngine upgraded shares of Akari Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research report on Monday, September 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $8.00.
Akari Therapeutics PLC Company Profile
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
Want to see what other hedge funds are holding AKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Akari Therapeutics PLC (NASDAQ:AKTX).
Receive News & Stock Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related stocks with our FREE daily email newsletter.